A shroom microdose is a very small amount of psilocybin mushrooms, typically between 0.1 and 0.5 grams of dried material, taken not to trip but to produce subtle shifts in mood, focus, or creativity. The dose is deliberately “sub-perceptual,” meaning you shouldn’t experience hallucinations, visual distortions, or the altered state of consciousness associated with a full psychedelic experience.
How Much Counts as a Microdose
The standard range is 0.1 to 0.5 grams of dried psilocybin mushrooms, with most people starting at the lower end. For context, a moderate recreational dose is around 2 to 3.5 grams, so a microdose is roughly one-tenth to one-twentieth of that. The goal is to land just below the threshold where you’d notice any psychedelic effects. If colors look brighter or your thoughts start to feel unusual, the dose was too high to qualify as a microdose.
One complication is that psilocybin content varies significantly between mushroom species, between individual mushrooms of the same species, and even between the cap and stem of a single mushroom. A quarter gram of one batch could be noticeably stronger than the same weight from another. To get around this, people commonly grind an entire batch of dried mushrooms into a fine powder using a blade grinder, then mix thoroughly. This homogenization spreads the psilocybin evenly, so each measured dose contains a more consistent amount of the active compound.
What It Does in the Brain
When you eat psilocybin mushrooms, your body quickly converts the psilocybin into psilocin, the compound that actually crosses into your brain. Psilocin’s primary target is the serotonin 2A receptor, one of the docking sites your brain uses to regulate mood, perception, and cognition. At a full psychedelic dose, strong activation of this receptor produces the classic trip. At microdose levels, the activation is far milder, which is why proponents believe it can gently influence mood and thinking without the dramatic perceptual shifts.
Psilocin also interacts with other serotonin receptor types, which may contribute to its effects on emotional processing and anxiety. Animal research has shown that even a single dose of psilocybin can increase the density of connections between brain cells, a process linked to learning and mood regulation. Whether this happens at microdose levels in humans remains an open question.
What People Report Feeling
The most commonly reported benefits of microdosing include improved mood, greater emotional openness, and a sense of enhanced creativity or flow. Some users describe better sustained attention and working memory, along with a feeling of being more present in conversations and daily tasks. Observational studies have found that emotional empathy (the ability to feel what someone else feels) may be enhanced, while the more analytical side of social understanding stays roughly the same.
Effects on creativity follow an interesting pattern. Some research suggests creative and flexible thinking may actually dip initially but could improve over time with repeated dosing. Similarly, certain types of memory, like the ability to form new associations between concepts, appear more responsive to psilocybin than straightforward verbal recall.
Not all the reported effects are positive. In controlled studies, participants who received active microdoses reported more negative physical sensations, things like mild nausea, headaches, or a slightly uneasy body feeling, compared to those who received a placebo.
What Placebo-Controlled Trials Actually Show
Here’s the most important thing to understand about microdosing: when researchers test it rigorously, the benefits largely disappear. Two randomized, double-blind, placebo-controlled trials conducted at Leiden University found that microdosing psilocybin did not significantly improve attention, mood, cognitive control, or self-reported well-being compared to placebo. Some initial effects on social cognition, mood, and cognitive flexibility showed up in early analysis, but none survived statistical correction, meaning they were likely due to chance.
This pattern holds across multiple studies. Several other placebo-controlled experiments have similarly failed to find reliable acute changes in cognition or mood from microdoses. Participants in both active and placebo groups tended to report positive subjective experiences, which strongly suggests that expectation plays a major role. If you believe a microdose will make your day better, it often does, whether or not the capsule contained any psilocybin.
One area where microdoses do seem to produce measurable effects is time perception. Research on LSD microdoses (which act on the same receptors) found that participants consistently overestimated how much time had passed, suggesting that even sub-perceptual doses can alter basic perceptual processes. Whether this translates into practical cognitive benefits is unclear.
Common Dosing Schedules
People who microdose typically follow a structured schedule rather than taking a dose every day. The two most popular protocols are:
- The Fadiman protocol: One microdose every fourth day (dose on day one, then two days off, repeat) for several weeks, followed by a reset period of two to four weeks before starting again. This is the most widely used approach, named after psychologist James Fadiman.
- The Stamets protocol: A psilocybin microdose combined with non-psychoactive medicinal mushrooms (like lion’s mane) and other supplements, taken on a schedule of four days on, three days off. Mycologist Paul Stamets proposed this combination for its theoretical benefits to nerve cell growth, though this hasn’t been validated in human trials.
The off days are considered important. The serotonin 2A receptor can build tolerance quickly, so spacing out doses is meant to prevent diminishing effects. The reset periods help avoid building a long-term tolerance and provide a baseline for comparison.
A Potential Heart Health Concern
One safety issue that gets surprisingly little attention involves the heart. Both psilocybin and LSD are structurally similar to several medications that have been pulled from the market or restricted because they cause cardiac fibrosis and heart valve damage when taken regularly. These drugs cause problems by repeatedly activating a specific serotonin receptor (5-HT2B) found in heart tissue, which over time can cause the valve tissue to thicken and stiffen.
Because microdosing protocols involve repeated exposure over weeks, months, or sometimes years, researchers have flagged this as a concern worth investigating. No human studies have yet confirmed that microdosing causes heart valve changes, but no long-term safety studies have ruled it out either. This is a genuine gap in the evidence, not a theoretical footnote. People who microdose for extended periods are essentially running an uncontrolled experiment on themselves.
Legal Status in the United States
Psilocybin remains a Schedule I controlled substance under federal law, making it illegal to possess, grow, or distribute anywhere in the United States. However, the legal landscape at the state and local level has shifted considerably. Colorado became the second state (after Oregon) to pass broad psilocybin reform when voters approved Proposition 122 in 2022, which decriminalized personal possession and created a framework for supervised therapeutic use.
Several cities have gone further on their own. Ann Arbor, Detroit, Hazel Park, and Ypsilanti in Michigan have all made enforcement of laws against psilocybin and other plant-based psychedelics the lowest priority for local police. Similar resolutions have passed in cities across the country, though “lowest priority” is not the same as legal. Federal prosecution remains possible regardless of local policy, and purchasing psilocybin mushrooms commercially is not legal in any state.